@article{cb95a8728f1d42e892db29139aad50ed,
title = "A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes",
author = "Sharon Mitchell and B. Malanda and Albertino Damasceno and Eckel, {Robert H.} and Dan Gaita and Kornelia Kotseva and Januzzi, {James L.} and George Mensah and J. Plutzky and Maksym Prystupiuk and Lars Ryden and J. Thierer and Virani, {Salim S.} and Laurence Sperling",
note = "Funding Information: The corporate partners supporting the World Heart Federation Roadmap Programme include Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi. The corporate partners supporting the World Heart Federation Roadmap Programme include Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi. The authors would like to thank all those who played a role in bringing this Roadmap to publication. There are a number of persons and institutions needing mention: Emory University, where the face-to-face expert writing group meeting took place; to the local experts who actively contributed to the meeting including Dr. Mehta Anurag, Dr. Devinder Dhindsa, Ty Kraniak, and Dr. Amy Scheel; and to Dr. Laura Gaita, diabetologist, who substantially contributed to the “Treatment and approaches to care” section. The authors also thank DiaTribe, who have engaged in numerous discussions about the role of patients and patient perspectives in this Roadmap. The modified Delphi process involved 2 rounds of surveys sent to all WHF and IDF Members with responses of 161 and 66 responses, respectively. Information gathered was essential to the development of the Roadmap, and we thank all those who took the time to complete the survey and send their feedback. A number of Members were actively involved in providing feedback, and specifically the authors would like to thank the Fondation Ha{\"i}tienne de Diab{\`e}te et de Maladies Cardio-vasculaires, the Swaziland Ministry of Health, and the Japan Diabetes Society. The authors would also like to thank WHF through the development of this roadmap. The corporate partners supporting the World Heart Federation Roadmap Programme include Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi.",
year = "2019",
month = sep,
doi = "10.1016/j.gheart.2019.07.009",
language = "English",
volume = "14",
pages = "215--240",
journal = "Global Heart",
issn = "2211-8160",
publisher = "Elsevier Science & Technology",
number = "3",
}
